Holen Sie sich die Stockscreener-App
0.345
23.12%
0.0667
Schlusskurs vom Vortag:
$0.2783
Offen:
$0.2876
24-Stunden-Volumen:
19.16M
Relative Volume:
10.03
Marktkapitalisierung:
$55.04M
Einnahmen:
$506.20K
Nettoeinkommen (Verlust:
$-42.05M
KGV:
-1.3034
EPS:
-0.2647
Netto-Cashflow:
$-31.36M
1W Leistung:
+43.97%
1M Leistung:
+18.16%
6M Leistung:
-81.38%
1J Leistung:
-84.70%
1-Tages-Spanne:
$0.27
$0.348
1-Wochen-Bereich:
$0.2262
$0.348
52-Wochen-Spanne:
$0.20
$3.05
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Firmenname
Mereo Biopharma Group Plc Adr
Sektor
Branche
Telefon
4403330237300
Adresse
ONE CAVENDISH PLACE, LONDON
Compare MREO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.3448 | 44.42M | 506.20K | -42.05M | -31.36M | -0.2647 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-12-30 | Herabstufung | Jefferies | Buy → Hold |
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-13 | Fortgesetzt | BTIG Research | Buy |
| 2022-08-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-05 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Needham | Buy |
Alle ansehen
Mereo Biopharma Group Plc Adr Aktie (MREO) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - Eastern Progress
Mereo BioPharma shareholders approve all resolutions at annual meeting - Investing.com
Mereo BioPharma shareholders approve all resolutions at annual meeting By Investing.com - Investing.com South Africa
Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers - Stock Titan
Mereo BioPharma Reports Q1 2026 Financial Results and Updates on Setrusumab, Alvelestat, and Vantictumab Clinical Progress - Minichart
Mereo BioPharma (NASDAQ: MREO) Q1 2026 loss narrows as setrusumab data mixed - Stock Titan
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Mereo BioPharma Reports Q1 2026 Financial Results, Advances Setrusumab and Alvelestat Clinical Programs, and Provides Cash Runway Update - Minichart
[10-Q] Mereo BioPharma Group plc Quarterly Earnings Report - Stock Titan
Mereo BioPharma (NASDAQ: MREO) halves Q1 loss and outlines key trial plans - Stock Titan
Trials miss fracture goals, but Mereo drug boosts bone density in OI - Stock Titan
Here's Why We're Not Too Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation - Sahm
MREO News | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
MREO Stock Price, Quote & Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
Mereo BioPharma (MREO) 2026 AGM to vote on share issuance, pay and directors - Stock Titan
MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - GlobeNewswire Inc.
MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - ChartMill
DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026 - ChartMill
Pomerantz LLP Shares Class Action Details With Shareholders in Mereo BioPharma Group plc – MREO - ACCESS Newswire
MREO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - chartmill.com
Pomerantz LLP Notifies Investors of Class Action Filing Against Mereo BioPharma Group plc – MREO - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - ChartMill
MREO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Mereo BioPharma Group plc Securities Lawsuit -- The Gross Law Firm - Barchart.com
Pomerantz LLP Reminds Shareholders: Securities Lawsuit Has Been Filed Against Mereo BioPharma Group plc – MREO - accessnewswire.com
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast - Defense World
Mereo BioPharma director Annalisa Jenkins to step down after annual meeting By Investing.com - Investing.com South Africa
Mereo BioPharma director Annalisa Jenkins to step down after annual meeting - Investing.com
Mereo BioPharma (NASDAQ: MREO) seeks £3.59M allotment authority; S-3 shelf $175M - Stock Titan
Mereo BioPharma (MREO) director Jenkins to leave board at May 2026 AGM - Stock Titan
MREO Deadline: MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
MREO Investor AlertMereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - ChartMill
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - FinancialContent
MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
Baird reiterates Mereo BioPharma stock rating after earnings By Investing.com - Investing.com South Africa
MREO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
Leerink reiterates Outperform on Mereo BioPharma stock at $2 By Investing.com - Investing.com South Africa
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights - Investing News Network
Mereo BioPharma (NASDAQ: MREO) details 2025 loss and cash runway to 2027 - Stock Titan
Finanzdaten der Mereo Biopharma Group Plc Adr-Aktie (MREO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):